Home Tags AACR 2016

Tag: AACR 2016

Phase I Trial of SGN-CD352A in Relapsed or Refractory Multiple Myeloma...

This week the first patient enrolled in a multi-center phase I clinical trial of SGN-CD352A for the treatment of patients with relapsed or refractory...

MM-310 Maximizes the Delivery and Local Activation of a Newly Engineered...

Positive, preclinical data evaluating MM-310, an antibody directed nano therapeutic or ADN that encapsulates a newly engineered form of the highly potent chemotherapy docetaxel as a...

Studies Show Glembatumumab Vedotin to be Effective in a Wide Range...

During the annual meeting of the American Association for Cancer Research (AACR) being held  April 16 - 20, 2016 in New Orleans, LA, Celldex...

Presurgery Combination of Trastuzumab Emtansine + Pertuzumab May Improve Outcomes of...

The I-SPY 2 TRIAL, a private-public partnership combining personalized medicine with a novel investigational design, is a neoadjuvant Phase II clinical trial screening agents in combination with...

OncoSec Medical’s ImmunoPulse IL-12 Primes Patients for an Enhanced Response to...

Melanoma is one of the most dangerous forms of skin cancer.  Based on recent data from the American Cancer Society, the disease accounts for...

Comparison of Three Different PD-L1 Diagnostic Tests Shows a High Degree of...

Three commercially available diagnostic tests were similarly effective in measuring PD-L1 protein expression on non-small cell lung cancer (NSCLC) tumor samples, indicating that health...

XMT-1536 Demonstrates Anti-Cancer Activity in Patients with NaPi2b-expressing Tumors

Preclinical data for Mersana Therapeutics' new immunoconjugate product candidate, XMT-1536, demonstrated significant anti-cancer activity in non-small cell lung cancer (NSCLC) and ovarian cancer tumor models. The...

AACR 2016: Companion and Complementary Diagnostics

Over the last decade, Targeted Therapies, Personalized and Precision Medicine have become part of our vocabulary, representing a new way of thinking in how...

X